Search
Thank you for joining us at the 2026 HPLC conference in Indianapolis
Although the conference has concluded, you can still access the scientific posters presented there. They showcase innovative chromatographic separations and mass spectrometry workflows for the characterization of complex biomolecules, including therapeutic proteins, oligonucleotides, nucleic acids, and proteomes.
Learn how Thermo Fisher Scientific is advancing chromatography and mass spectrometry technologies to support faster, more robust, and more comprehensive characterization workflows across biopharmaceutical research, development, and manufacturing.
Interested in hearing more about these applications or the solutions presented? Contact us and we’ll connect you with one of our experts to discuss your analytical challenges and workflow goals.
Featured experiences
Speakers
Don’t Miss Our Lunch Workshop
Wednesday, June 10
12:30-1:30 p.m.
ASOs, ADCs, and Other Therapeutics: Advanced Characterization with Novel Reversed-Phase Columns and Integrated LC–MS Platform
Biotherapeutics are becoming increasingly structurally diverse, placing greater demands on analytical platforms that can support efficient development and regulatory readiness. Reversed-phase chromatography (RPC) remains a widely adopted and adaptable technique, supporting applications that range from oligonucleotide analysis to detailed protein characterization and post-translational modification assessment.
This seminar explores the integration of a macroporous, monodisperse reversed-phase column with a next-generation bioinert LC system for the analysis of two emerging classes of biotherapeutics. Antisense oligonucleotides were examined under optimized chromatographic conditions, using a design-of-experiments strategy to evaluate how ion-pairing reagents influence both LC separation and downstream MS performance. The platform was further applied to antibody–drug conjugates, combining RPC with Orbitrap mass spectrometry to support multi-level characterization. Intact, sub-unit, and bottom-up analyses enabled drug-to-antibody ratio determination alongside detailed PTM profiling — including glycosylation, oxidation, and deamidation — under native and stress conditions. Collectively, these studies demonstrate a streamlined and adaptable workflow for comprehensive biotherapeutic characterization.
Sara Carillo, Ph.D.
Bioanalytical Research Lead, Characterization and Comparability Laboratory National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
Sara Carillo completed her Ph.D. in chemical sciences in 2013 at the University of Naples Federico II, where she focused on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria using NMR and mass spectrometry techniques. In 2015, she joined the CCL group at NIBRT, led by Prof. Jonathan Bones. She began her postdoctoral research investigating the effects of extractables and leachables from single-use bioreactors on both the CHO cell N-glycome and the monoclonal antibodies they produce. She currently serves as Bioanalytical Research Lead at NIBRT, where her work centers on developing new mass spectrometry–based analytical approaches to enable deeper and more accessible understanding of biomanufacturing processes and the structural complexity of biopharmaceuticals.
Mauro De Pra, Ph.D.
Product Marketing Manager, LC Columns
Sara Carillo completed her Ph.D. in chemical sciences in 2013 at the University of Naples Federico II, where she focused on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria using NMR and mass spectrometry techniques. In 2015, she joined the CCL group at NIBRT, led by Prof. Jonathan Bones. She began her postdoctoral research investigating the effects of extractables and leachables from single-use bioreactors on both the CHO cell N-glycome and the monoclonal antibodies they produce. She currently serves as Bioanalytical Research Lead at NIBRT, where her work centers on developing new mass spectrometry–based analytical approaches to enable deeper and more accessible understanding of biomanufacturing processes and the structural complexity of biopharmaceuticals.